168 related articles for article (PubMed ID: 37762486)
1. Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.
Maeoka R; Nakazawa T; Matsuda R; Morimoto T; Shida Y; Yamada S; Nishimura F; Nakamura M; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762486
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.
Tanaka Y; Nakazawa T; Nakamura M; Nishimura F; Matsuda R; Omoto K; Shida Y; Murakami T; Nakagawa I; Motoyama Y; Morita H; Tsujimura T; Nakase H
PLoS One; 2019; 14(3):e0212455. PubMed ID: 30840664
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis.
Morimoto T; Nakazawa T; Matsuda R; Maeoka R; Nishimura F; Nakamura M; Yamada S; Park YS; Tsujimura T; Nakagawa I
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397112
[TBL] [Abstract][Full Text] [Related]
6. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
7. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638384
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Haspels HN; Rahman MA; Joseph JV; Gras Navarro A; Chekenya M
Front Immunol; 2018; 9():1345. PubMed ID: 29967607
[TBL] [Abstract][Full Text] [Related]
10. Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas.
Sönmez C; Wölfer J; Holling M; Brokinkel B; Stummer W; Wiendl H; Thomas C; Schulte-Mecklenbeck A; Grauer OM
Sci Rep; 2022 Apr; 12(1):6769. PubMed ID: 35474089
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.
Nakazawa T; Nakamura M; Matsuda R; Nishimura F; Park YS; Motoyama Y; Hironaka Y; Nakagawa I; Yokota H; Yamada S; Tamura K; Takeshima Y; Omoto K; Tanaka Y; Ouji Y; Yoshikawa M; Tsujimura T; Nakase H
J Neurooncol; 2016 Sep; 129(2):231-41. PubMed ID: 27393349
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
13. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Front Immunol; 2018; 9():824. PubMed ID: 29740437
[TBL] [Abstract][Full Text] [Related]
14.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Nakase H; Tsujimura T
Regen Ther; 2022 Dec; 21():185-191. PubMed ID: 35919498
[TBL] [Abstract][Full Text] [Related]
16. An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood.
Nakazawa T; Maeoka R; Morimoto T; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
Regen Ther; 2023 Dec; 24():32-42. PubMed ID: 37303464
[TBL] [Abstract][Full Text] [Related]
17. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
Lee SJ; Kang WY; Yoon Y; Jin JY; Song HJ; Her JH; Kang SM; Hwang YK; Kang KJ; Joo KM; Nam DH
BMC Cancer; 2015 Dec; 15():1011. PubMed ID: 26704632
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
[TBL] [Abstract][Full Text] [Related]
19. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]